SCHEMBL5365553

SCHEMBL5365553

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(Br)ccc1O)C(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 1/20 0.53
SRC P12931 5/20 0.52
NTRK1 P04629 4/20 0.52
SYK P43405 3/20 0.52
FCER2 P06734 2/20 0.52
NTRK3 Q16288 2/20 0.52
NTRK2 Q16620 2/20 0.52
CDK2 P24941 2/20 0.51
KDR P35968 3/20 0.49
MAP1LC3B Q9GZQ8 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LCK P06239 2/20 0.47
FYN P06241 2/20 0.47
YES1 P07947 2/20 0.47
PDGFRB P09619 2/20 0.47
FGFR1 P11362 2/20 0.47
AURKA O14965 1/20 0.45
RPS6KA3 P51812 1/20 0.45
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369883 0.89 NTRK1 (0.55) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5365765 0.87 SRC (0.52) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5367143 0.87 SRC (0.52) PLK4SRCNTRK1SYKFCER2
SCHEMBL5365279 0.85 SYK (0.68) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5360933 0.85 MAP3K7 (0.58) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5363782 0.85 NOX4 (0.57) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5376914 0.84 SYK (0.58) PLK4SRCNTRK1SYKFCER2
SCHEMBL5364692 0.83 SRC (0.52) SRCNTRK1SYKFCER2NTRK3
SCHEMBL5358229 0.83 LRRK2 (0.64) PLK4SRCNTRK1CDK2KDR
SCHEMBL5367229 0.83 NTRK1 (0.55) SRCNTRK1SYKFCER2NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PLK4 42/4885SRC 189/4885NTRK1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.